MC is a 62 year old male with a 17 year history of Parkinson’s Disease. MC was initially diagnosed with Parkinson’s type resting pill-rolling tremor affecting his left hand and then progressing to the limbs on left side of his body. Over the course of five years the tremors increased gradually affecting the right side as well. At ten years into the disease process, MC was no longer able to practice as an attorney, mobility was affected and limitations increased compromising his personal and professional abilities.

In 2009, before the treatment of SE, the left side tremors had significantly worsened, symptoms of stiffness and bradykinesia which introduced a shuffling gait and poor balance made it unsafe for HM to ambulate without the use of a cane. At the time MC began consuming SE he was unable to dress himself, put on his watch, write, feed himself or drive his car.

After 45 days on the product, consuming 1 gram of SE, three times per day, MC showed significant improvement with decreased tremors, less stiffening and bradykinesia; at this time MC was able to get around without the use of his cane.

After 60 days on the product, judging that the benefits had plateaued, MC discontinued the use of SE.
Forty – five days later, signs of tremor and bradykinesia returned and MC was seeking medical attention, once again.

MC resumed SE with a dose of 2 grams, three times per day and within six weeks showed much improvement with less tremors, stiffness and bradykinesia. MC was able to participate in activities of daily living, such as dressing and feeding himself, he was also able to tie his own tie, put on his watch, and once again, he could ambulate without using a cane. To date MC has been on SE for two years, he has returned to driving his car without limitations, he is independent with all activities of daily living and he also participates in some level of professional activity.

Another patient, MT, is a 52 year old woman with an early onset of Parkinson at age 36, with tremor as the primary symptom. Early treatment consisted of Pergolid, then Budipin up to 30 mg three times a day. However due to QTc increase, Budipin was later reduced to 10 mg three times a day. The patient was also treated with Methydopamin 62.5 mg four times a day. With this treatment, MT’s main problem was the experience of fluctuations and Tissue Regeneration – From Basic Biology to Clinical Application 184 the beginning of ON-OFF syndrome.

One year ago MT began consuming StemEnhance 1gram three times a day. Today MT’s experiences only minor tremor accompanied with some dyskinetic syndrome and sometimes propulsion. Her quality of life has increased and she is much more socially active.

Christian Drapeau, a member of Gitte Jensen, Ph.D, research team that created the patented Stem Enhance ULTRA